Clinical implications of endogenous testosterone density on prostate cancer progression in patients with very favorable low and intermediate risk treated with radical prostatectomy.
Journal
Asian journal of andrology
ISSN: 1745-7262
Titre abrégé: Asian J Androl
Pays: China
ID NLM: 100942132
Informations de publication
Date de publication:
06 Jan 2023
06 Jan 2023
Historique:
received:
03
08
2022
accepted:
31
10
2022
pubmed:
12
1
2023
medline:
12
1
2023
entrez:
11
1
2023
Statut:
aheadofprint
Résumé
We tested the association between endogenous testosterone density (ETD; the ratio between endogenous testosterone [ET] and prostate volume) and prostate cancer (PCa) aggressiveness in very favorable low- and intermediate-risk PCa patients who underwent radical prostatectomy (RP). Only patients with prostate-specific antigen (PSA) within 10 ng ml -1 , clinical stage T1c, and International Society of Urological Pathology (ISUP) grade group 1 or 2 were included. Preoperative ET levels up to 350 ng dl -1 were classified as abnormal. Tumor quantitation density factors were evaluated as the ratio between percentage of biopsy-positive cores and prostate volume (biopsy-positive cores density, BPCD) and the ratio between percentage of cancer invasion at final pathology and prostate weight (tumor load density, TLD). Disease upgrading was coded as ISUP grade group >2, and progression as recurrence (biochemical and/or local and/or distant). Risk associations were evaluated by multivariable Cox and logistic regression models. Of 320 patients, 151 (47.2%) had intermediate-risk PCa. ET (median: 402.3 ng dl -1 ) resulted abnormal in 111 (34.7%) cases (median ETD: 9.8 ng dl -1 ml -1 ). Upgrading and progression occurred in 109 (34.1%) and 32 (10.6%) cases, respectively. Progression was predicted by ISUP grade group 2 (hazard ratio [HR]: 2.290; P = 0.029) and upgrading (HR: 3.098; P = 0.003), which was associated with ISUP grade group 2 (odds ratio [OR]: 1.785; P = 0.017) and TLD above the median (OR: 2.261; P = 0.001). After adjustment for PSA density and body mass index (BMI), ETD above the median was positively associated with BPCD (OR: 3.404; P < 0.001) and TLD (OR: 5.238; P < 0.001). Notably, subjects with abnormal ET were more likely to have higher BPCD (OR: 5.566; P = 0.002), as well as TLD (OR: 14.998; P = 0.016). Independently by routinely evaluated factors, as ETD increased, BPCD and TLD increased, but increments were higher for abnormal ET levels. In very favorable cohorts, ETD may further stratify the risk of aggressive PCa.
Identifiants
pubmed: 36629157
pii: 367317
doi: 10.4103/aja202298
pmc: PMC10521947
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2023 Copyright: © The Author(s)(2023).
Références
World J Urol. 2020 Apr;38(4):957-964
pubmed: 31154465
J Urol. 2005 Jun;173(6):1935-7
pubmed: 15879785
Int Urol Nephrol. 2022 Mar;54(3):541-550
pubmed: 35044553
Urology. 2007 Mar;69(3):495-9
pubmed: 17382152
Oncotarget. 2017 Mar 14;8(11):18424-18434
pubmed: 27793023
Int J Impot Res. 2009 Jan-Feb;21(1):1-8
pubmed: 18923415
Eur Urol. 2006 Nov;50(5):1006-13
pubmed: 16959399
J Natl Compr Canc Netw. 2004 May;2(3):224-48
pubmed: 19795607
Urol Int. 2017;98(1):32-39
pubmed: 27798942
BJU Int. 2021 Mar;127(3):318-325
pubmed: 32869940
Minerva Urol Nefrol. 2020 Feb;72(1):66-71
pubmed: 30298710
Eur Urol. 2021 Feb;79(2):243-262
pubmed: 33172724
Aging Clin Exp Res. 2021 May;33(5):1399-1401
pubmed: 32557331
Urology. 2021 Sep;155:96-100
pubmed: 34087311
Asian J Androl. 2020 May-Jun;22(3):323-329
pubmed: 31347517
Eur Urol. 2017 Jul;72(1):84-109
pubmed: 28126351
Int Urol Nephrol. 2020 Jul;52(7):1261-1269
pubmed: 32016908
Eur Urol Oncol. 2018 Oct;1(5):411-417
pubmed: 31158080
CA Cancer J Clin. 2021 Jan;71(1):7-33
pubmed: 33433946
Aging Male. 2002 Sep;5(3):170-6
pubmed: 12471777
Cancer. 2011 Sep 1;117(17):3953-62
pubmed: 21365624
Eur Urol. 2012 Mar;61(3):480-7
pubmed: 22078338
J Urol. 2003 May;169(5):1670-5
pubmed: 12686805
Urology. 2014 Jan;83(1):28-32
pubmed: 24269219
Eur Urol. 2016 Mar;69(3):428-35
pubmed: 26166626
World J Urol. 2020 Nov;38(11):2799-2809
pubmed: 31980875
BJU Int. 2012 Feb;109(4):520-4
pubmed: 21851535
Mod Pathol. 2011 Jan;24(1):16-25
pubmed: 20818340
Urol Int. 2019;103(1):25-32
pubmed: 31067558
Am J Surg Pathol. 2005 Sep;29(9):1228-42
pubmed: 16096414
World J Urol. 2013 Jun;31(3):481-8
pubmed: 23512231
Urol Int. 2019;103(4):400-407
pubmed: 31163438
Minerva Urol Nefrol. 2019 Apr;71(2):136-145
pubmed: 30767495
Int Urol Nephrol. 2021 May;53(5):843-854
pubmed: 33389506
Urol Int. 2020;104(5-6):465-475
pubmed: 31991418
J Urol. 2015 Feb;193(2):403-13
pubmed: 25260832